All Stories

  1. External validation of the Uromonitor®‐version 2 urine test as a biomarker for optimisation of non‐muscle‐invasive bladder cancer management
  2. Integration of Primary Care Into the Follow‐Up Protocol for Prostate Cancer Patients in Aragon, Spain. It Is Time to Follow Other Successful Models in the Region
  3. Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results
  4. Effect of the Consumption of Lean Red Meat from Beef (Pirenaica Breed) Versus Lean White Meat (Chicken) on the Gut Microbiota: A Randomized Cross‐Over Study in Healthy Young Adults
  5. Re: Letter to the editor: “Diagnostic capacity and interobserver variability in FIGO, ACOG, NICE and Chandraharan cardiotocographic guidelines to predict neonatal acidemia” The authors should reconsider their conclusions
  6. FRI-516 Impact of comorbidities on liver transplant outcomes: assessing sex-specific differences by using machine learning analysis
  7. MP08-10 REAL WORLD EVIDENCE OF UROMONITOR FOR NMIBC FOLLOW UP BY THE CUETO GROUP; CENTRALIZED VERSUS LOCAL PERFORMANCE
  8. Integrating radiological and clinical data for clinically significant prostate cancer detection with machine learning techniques
  9. External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors
  10. Diagnosis of cardiotocographic sinusoidal patterns by spectral analyses
  11. Reducing the demand for magnetic resonance imaging scans and prostate biopsies during the early detection of clinically significant prostate cancer: Applying the Barcelona risk-stratified pathway in Catalonia
  12. The utility of fetal heart rate deceleration's descending slope in searching for a non‐National Institute of Child Health and Human Development parameter for the detection of fetal acidosis
  13. Interplay of the Mediterranean diet and genetic hypertension risk on blood pressure in European adolescents: Findings from the HELENA study
  14. Prostate Cancer and the Mevalonate Pathway
  15. Investigating Efficient Risk-Stratified Pathways for the Early Detection of Clinically Significant Prostate Cancer
  16. The body mass index increases the genetic risk scores' ability to predict risk of hepatic damage in European adolescents: The HELENA study
  17. Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer
  18. Machine Learning Algorithms Combining Slope Deceleration and Fetal Heart Rate Features to Predict Acidemia
  19. Development of a genetic risk score to predict the risk of hypertension in European adolescents from the HELENA study
  20. Postnatal catch-up growth in term newborns with altered fetal weight patterns. The GROWIN study
  21. Comparing the Min–Max–Median/IQR Approach with the Min–Max Approach, Logistic Regression and XGBoost, Maximising the Youden Index
  22. Clinically Significant Prostate Cancer Early Detection using Risk-Organized Models (ROMs)
  23. A multistate model and its standalone tool to predict hospital and ICU occupancy by patients with COVID-19
  24. Epidemiology, Diagnosis and Management of Penile Cancer: Results from the Spanish National Registry of Penile Cancer
  25. Testosterone Recovery after Androgen Deprivation Therapy in Prostate Cancer: Building a Predictive Model
  26. A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand
  27. Evaluation of Characteristics and Building Applications of Multi-Recycled Concrete Aggregates from Precast Concrete Rejects
  28. The True Utility of Predictive Models Based on Magnetic Resonance Imaging in Selecting Candidates for Prostate Biopsy
  29. Impact of comorbidities on liver transplantation: a prospective and multicentric study
  30. Digital Competences. The challenge of their acquisition and verification in the University Degree
  31. Comparative Analysis of PSA Density and an MRI-Based Predictive Model to Improve the Selection of Candidates for Prostate Biopsy
  32. Mortality and Causes of Death After Liver Transplantation: Analysis of Sex Differences in a Large Nationwide Cohort
  33. Personalized Model to Predict Small for Gestational Age at Delivery Using Fetal Biometrics, Maternal Characteristics, and Pregnancy Biomarkers: A Retrospective Cohort Study of Births Assisted at a Spanish Hospital
  34. A Stepwise Algorithm for Linearly Combining Biomarkers under Youden Index Maximization
  35. Multiparametric Magnetic Resonance Imaging Grades the Aggressiveness of Prostate Cancer
  36. The Barcelona Predictive Model of Clinically Significant Prostate Cancer
  37. Confinement of FRP concrete columns: Review of design guidelines and comparison with experimental results
  38. Machine Learning Algorithm to Predict Acidemia Using Electronic Fetal Monitoring Recording Parameters
  39. Teaching Urology to Undergraduates: A Prospective Survey of What General Practitioners Need to Know
  40. Diagnostic capacity and interobserver variability in FIGO, ACOG, NICE and Chandraharan cardiotocographic guidelines to predict neonatal acidemia
  41. Perinatal Adverse Effects in Newborns with Estimated Loss of Weight Percentile between the Third Trimester Ultrasound and Delivery. The GROWIN Study
  42. Incorporating a New Summary Statistic into the Min–Max Approach: A Min–Max–Median, Min–Max–IQR Combination of Biomarkers for Maximising the Youden Index
  43. Changes in severity, mortality, and virus genome among a Spanish cohort of patients hospitalized with SARS-CoV-2
  44. A Clinical Decision Web to Predict ICU Admission or Death for Patients Hospitalised with COVID-19 Using Machine Learning Algorithms
  45. Predictive Value of Genetic Risk Scores in the Development of Colorectal Adenomas
  46. Ultrasound diagnosis of late-onset fetal growth restriction
  47. Role of PCA3 and SelectMDx in the optimization of active surveillance in prostate cancer
  48. Papel de PCA3 y SelectMDx en la optimización de la vigilancia activa en el cáncer de próstata
  49. Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice
  50. A predictive tool for clinically significant prostate cancer detection in men with prostate cancer suspicion
  51. Total intrapartum fetal reperfusion time (fetal resilience) and neonatal acidemia
  52. Screening of severe acute respiratory syndrome coronavirus-2 infection during labor and delivery using polymerase chain reaction and immunoglobulin testing
  53. Development of a Genetic Risk Score to predict the risk of overweight and obesity in European adolescents from the HELENA study
  54. Mediterranean Diet, Screen-Time-Based Sedentary Behavior and Their Interaction Effect on Adiposity in European Adolescents: The HELENA Study
  55. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) universal screening in gravids during labor and delivery
  56. Reduced Growth in Non-Small for Gestational Age Fetuses from 35 Weeks of Gestation to Birth and Perinatal Outcomes
  57. Interaction Effect of the Mediterranean Diet and an Obesity Genetic Risk Score on Adiposity and Metabolic Syndrome in Adolescents: The HELENA Study
  58. Prediction of clinically significant prostate cancer after negative prostate biopsy: The current value of microscopic findings
  59. A cohort study of fetal growth in twin pregnancies by chorionicity: comparison with European and American standards
  60. Actualización y optimización de la vigilancia activa en cáncer de próstata en 2021
  61. Prediction of Large for Gestational Age by Ultrasound at 35 Weeks and Impact of Ultrasound-Delivery Interval: Comparison of 6 Standards
  62. Mastectomía contralateral profiláctica con reconstrucción inmediata en pacientes con cáncer de mama unilateral sin mutación germinal en BRCA1/2
  63. Validation of a 2‐gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population
  64. Types of pathological progression within Spanish Register on Active Surveillance and their relevance in radical prostatectomy specimens
  65. Las biopsias de próstata dirigidas ¿están listas para reemplazar las biopsias de próstata sistemáticas?
  66. How to implement magnetic resonance imaging before prostate biopsy in clinical practice: nomograms for saving biopsies
  67. Pregestational body mass index, trimester-specific weight gain and total gestational weight gain: how do they influence perinatal outcomes?
  68. Detection of Adverse Perinatal Outcomes at Term Delivery Using Ultrasound Estimated Percentile Weight at 35 Weeks of Gestation: Comparison of Five Fetal Growth Standards
  69. Clinical utility of thrombophilia, anticoagulant treatment, and maternal variables as predictors of placenta-mediated pregnancy complications: an extensive analysis
  70. External validation of SelectMDx (v1) in an opportunistic screening cohort in first TRUS-guided biopsy without MRI imaging
  71. Role of the 4Kscore test as a predictor of reclassification in prostate cancer active surveillance
  72. MP12-19 4KSCORE TEST AS A PREDICTOR OF RECLASSIFICATION IN PROSTATE CANCER ACTIVE SURVEILLANCE
  73. Variabilidad dentro del Registro Nacional multicéntrico en Vigilancia Activa; cuestionario a urólogos
  74. Maternal morbidity after implementation of a postpartum hemorrhage protocol including use of misoprostol
  75. Variability within the national registry of active surveillance in prostate cancer in Spain
  76. The management of active surveillance in prostate cancer: Validation of the Canary Prostate Active Surveillance Study risk calculator with the Spanish Urological Association Registry
  77. Physico-mechanical properties of multi-recycled self-compacting concrete prepared with precast concrete rejects
  78. Comparison of fetal weight distribution improved by paternal height by Spanish standard versus Intergrowth 21st standard
  79. MP43-12 PREDICTING PROGRESSION IN ACTIVE SURVEILLANCE; EXTERNAL VALIDATION OF THE CANARY PASS RISK CALCULATOR WITH THE SPANISH UROLOGICAL ASSOCIATION REGISTRY ON AS
  80. MP53-05 TESTOSTERONE RECOVERY AFTER LONG TIME DEPRIVATION THERAPY: PREDICITIVE FACTORS AND MODELS (NOMOGRAMS)
  81. Testosterone recovery after long time androgen deprivation therapy: The role of duration of deprivation in combination with other predictive factors
  82. Physico – mechanical properties of multi – recycled concrete from precast concrete industry
  83. 4Kscore Test, Prostate Cancer Prevention Trial-Risk Calculator y European Research Screening Prostate-Risk Calculator en la predicción del cáncer de próstata de alto grado; estudio preliminar
  84. Programa de monitorización de la vigilancia activa en cáncer de próstata en España de la Sociedad Española de Urología; resultados preliminares
  85. Preliminary results of the Spanish Association of Urology National Registry in Active Surveillance for prostate cancer
  86. Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy
  87. Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy
  88. 343 Optimizing use of PCA3 in initial prostate biopsy: External validation of a proposed nomogram and proposal for a new system to choose cut-off points in nomograms
  89. Urología y recursos predictivos en la Web
  90. Implementing the use of nomograms by choosing threshold points in predictive models: 2012 updated P artin T ables vs a E
  91. Construction of Nomograms for Predicting the Development of Metastases and Biochemical Failure in Cancer of Prostate Treated With Radiation Therapy From Patients of Spanish Cancer Prostate Register (RECAP)
  92. Genetic predisposition to early recurrence in clinically localized prostate cancer
  93. 1468 VALUE OF PERINEURAL INVASION, LYMPHOVASCULAR INVASION AND MULTICENTRICITY IN RADICAL PROSTATECTOMY SPECIMENS AS A PREDICTORS OF BIOCHEMICAL RELAPSE IN ORGAN-CONFINED PROSTATE CANCER
  94. 975 Value of perineural invasion, lymphovascular invasion and multicentricity in radical prostatectomy specimens as a predictors of biochemical relapse in organ-confined prostate cancer
  95. 977 Postoperative nomogram predicting the probability of biochemical recurrence after radical prostatectomy for prostate cancer
  96. A step-by-step algorithm for combining diagnostic tests
  97. Vigencia actual de los nomogramas en la estadificación del cáncer de próstata